- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05633147
Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam
Effect of Repeated Dosing of Clarithromycin on PK of Linaprazan Glurate/Linaprazan, Effect of Single Dose of Linaprazan Glurate on PK of Clarithromycin, Single/Repeated Dosing of Linaprazan Glurate on PK of Midazolam to Healthy Subjects
Study Overview
Status
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Teresa Sandvall
- Phone Number: +46 (0)76 492 21 63
- Email: teresa.sandvall@sdslifescience.com
Study Contact Backup
- Name: Kajsa Larsson, PhD
- Phone Number: +46 (0)70 675 01 28
- Email: kajsa.larsson@cincluspharma.com
Study Locations
-
-
-
Uppsala, Sweden, 75237
- CTC Clinical Trials Consultants AB
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Main Inclusion Criteria:
- Willing and able to give written informed consent for participation in the study.
- Healthy male and female subjects of non-childbearing potential aged 18 to 60 years, inclusive.
- Body mass index ≥ 18.0 and ≤ 30.0 kg/m2.
- Subjects as well as their partners, must agree to contraception requirements. Male subjects must refrain from donating sperm.
Main Exclusion Criteria:
- Have known allergies to any components of the linaprazan glurate formulation, to clarithromycin/midazolam or to any drugs of a similar class including excipients associated with any of the drugs.
- Use of CYP3A4 inhibitors, antacids, PPIs or any medication that changes gastric pH.
- Use of any prescribed or non-prescribed CYP3A4-inducing medication or other metabolic enzyme inducers.
- History of any clinically significant disease or disorder defined in the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: linaprazan glurate
Part I: Linaprazan glurate in base form, 100 mg once daily will be administered under fasting conditions at day 1 and day 10. Part II: Linaprazan glurate hydrochloride (HCl), 75 mg twice a day for 13 days. The morning dose will be administered under fasting conditions on Day 2 and Day 14. |
Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).
Substrate for CYP3A.
Midazolam 2.5 mg once daily (2.5 mL oral solution).
Investigational Medicinal Product: Linaprazan glurate (tablets). Part I: Linaprazan glurate in base form, 100 mg once daily Day 1 and Day 10. Part II: Linaprazan glurate hydrochloride (HCl), 75 mg twice daily for 13 days. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part I - Linaprazan glurate and linaprazan PK parameters with and without co-administration of clarithromycin - Area under the plasma concentration curve
Time Frame: Day 1 to day 13
|
Area under the plasma concentration curve from 0 to infinity (AUCinf)
|
Day 1 to day 13
|
Part I - Linaprazan glurate and linaprazan PK parameters with and without co-administration of clarithromycin - AUC 0-t
Time Frame: Day 1 to day 13
|
AUC from time 0 to time t (AUC 0-t)
|
Day 1 to day 13
|
Part I - Linaprazan glurate and linaprazan PK parameters with and without co-administration of clarithromycin - Maximum plasma concentration
Time Frame: Day 1 to day 13
|
Maximum plasma concentration (Cmax)
|
Day 1 to day 13
|
Part II- Midazolam PK parameters in the presence and absence of linaprazan glurate administration - Area under the plasma concentration curve
Time Frame: Day 1 to day 16
|
AUCinf
|
Day 1 to day 16
|
Part II- Midazolam PK parameters in the presence and absence of linaprazan glurate administration - AUC 0-t
Time Frame: Day 1 to day 16
|
AUC 0-t
|
Day 1 to day 16
|
Part II- Midazolam PK parameters in the presence and absence of linaprazan glurate
Time Frame: Day 1 to day 16
|
Cmax
|
Day 1 to day 16
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Karin Palm, CTC Clinical Trial Consultants AB
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Central Nervous System Depressants
- Enzyme Inhibitors
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Anti-Bacterial Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Protein Synthesis Inhibitors
- Midazolam
- Clarithromycin
Other Study ID Numbers
- CX842A2105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacokinetics
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Methotrexate | Pharmacokinetics of 7-hydroxymethotrexateUnited States
-
Astellas Pharma IncCompletedHealthy | Pharmacokinetics of ASP1941 | Pharmacokinetics of MitiglinideJapan
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MethadoneUnited States
-
Astellas Pharma IncBasilea PharmaceuticaCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MidazolamUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of DigoxinUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of BupropionUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of SirolimusUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of AtorvastatinUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Caffeine | Pharmacokinetics of RepaglinideUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MetforminUnited States
Clinical Trials on Drug drug interaction (DDI) - Clarithromycin (Part I)
-
Hospital Italiano de Buenos AiresCompleted
-
University of ChicagoRecruitingCancer | Advanced Solid Tumor | Advanced Cancer | Behavior Disorders | Mental Health IssueUnited States
-
University of ZurichUniversity Hospital, Zürich; Center of Competence Multimorbidity, ZurichCompletedDiabetes Complications | Gastrointestinal Hemorrhage | MultimorbiditySwitzerland
-
GlaxoSmithKlineTerminated
-
Beijing Biostar Pharmaceuticals Co., Ltd.RecruitingAdvanced Solid TumorChina
-
Chong Kun Dang PharmaceuticalUnknownCardiovascular DiseasesKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedCardiovascular DiseasesKorea, Republic of
-
Retinset SLInstituto Universitario de Oftalmobiología Aplicada (Institute of Applied...Completed
-
Chong Kun Dang PharmaceuticalCompletedCardiovascular DiseasesKorea, Republic of